hims hers semaglutide Wegovy® Pill and Wegovy® Pen Now Available with & Hims & Hers Stock Tumbles

This dual mechanism allows Mounjaro to potentially offer stronger effects on both insulin control and appetite regulation

These factors, combined with the continuous rise in diabetes and obesity rates and the anticipated economic burden of such conditions, are expected to drive up the demand for relevant treatments or prevention methods

Contact your healthcare provider for persistent, worsening pain, or pain accompanied by numbness, tingling, or weakness

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound) in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity

1 Although GLP-1 RAs are considered to have effects on both fasting and prandial glucose control, evidence suggests that the shorter-acting agents (exenatide and liraglutide) have a greater effect on postprandial values compared to the weekly administered GLP-1 RAs

Together, these two studies elucidate pathways that inform strategies coupling GLP-1R signaling to control of body weight in patients with diabetes or obesity